References
- Weerasooriya R, Khairy P. Litalien J, Made L, Hocini M, Sacher F, Lellouche N, Knecht S. Wright M, Nault I, Miyazaki 5, Scavee C, Clementy J, Haissaguerre M, Jais P. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011; 57:160-6.
- Sherman DG. Stroke prevention in atrial fibrillation pharmacologic rate versus rhythm control. Stroke 2007; 38: 615–7.
- Gage B, Boechler M, Doggette A, Fortune G, Flaker G, Rich M, Radford M. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicarebeneficiaries with chronic atrial fibrillation. Stroke 2000; 31:822–7.
- Bayard YL, Omran H, Neuzil P, Thuesen L, Pichler M, Rowland E, Ramondo A, Ruzyllo W, Budts W, Montalescot G, Brugada P.Serruys PW, Vahanian A, Piéchaud JF, Bartorelli A, Marco J, Probst P. Kuck KH, Ostermayer SH, Bijscheck F, Fischer E, Leetz M, Sievert H. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. Eurolntervention 2010; 6:220–6.
- Block P. Burstein 5, Casale P. Kramer P. Teirstein P, Williams D, Reisman M. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy. 5 years results of the PLAATO Study. JACC Cardiovasc Interv 2009; 2: 594–600.
- Holmes D, Reddy V, Turi Z, Doshi 5, Sieverts, Buchbinder M, Mullin C, Sick P. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation :a randomised non-inferiority trial. Lancet 2009; 374: 534–42.